Development is moving to phase 2 LEGION-100-2a (NCT06533644) across global sites, with planned neoadjuvant prostate studies and expansion concepts in multiple solid tumors. Metastatic ...
Serial proteomic characterization of plasma extracellular vesicles (EV) to identify changes that predict outcomes in metastatic castrate-resistant prostate cancer (mCRPC) patients receiving 177Lu-PSMA ...
Cribriform-positive morphology was associated with a 3.6-fold higher risk for metastasis in patients with prostate cancer, and radiotherapy with neoadjuvant androgen deprivation therapy (ADT) was ...
A prospective study exploring genomic correlates of clinical outcome in patients with metastatic castration-sensitive prostate cancer receiving enzalutamide. This is an ASCO Meeting Abstract from the ...
Hello. It's Mark Kris from Memorial Sloan Kettering. Recently, I presented information about the published trials of neoadjuvant nivolumab chemotherapy vs chemotherapy, showing robust, disease-free ...
Hosted on MSN
ASCO 2026: A major prostate cancer trial shows drug can keep high-risk disease from returning for longer
For men diagnosed with high-risk prostate cancer, surgery is often part of the treatment plan, but nearly half of all patients who undergo radical prostatectomy for high-risk disease will see their ...
The second annual report from the National Cancer Database (NCDB) of the American College of Surgeons (ACS) documents a substantial rise in medication treatments, such as chemotherapy, immunotherapy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results